<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Leistner DM</submitter><funding>American Heart Association</funding><funding>Deutsche Stiftung für Herzforschung</funding><funding>National Heart, Lung, and Blood Institute</funding><funding>Berlin Institute of Health</funding><funding>NHLBI NIH HHS</funding><funding>German Centre for Cardiovascular Research</funding><funding>Abbott Vascular</funding><pagination>3549-3560</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7780480</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>41(37)</volume><pubmed_abstract>&lt;h4>Aims&lt;/h4>Acute coronary syndromes with intact fibrous cap (IFC-ACS), i.e. caused by coronary plaque erosion, account for approximately one-third of ACS. However, the underlying pathophysiological mechanisms as compared with ACS caused by plaque rupture (RFC-ACS) remain largely undefined. The prospective translational OPTICO-ACS study programme investigates for the first time the microenvironment of ACS-causing culprit lesions (CL) with intact fibrous cap by molecular high-resolution intracoronary imaging and simultaneous local immunological phenotyping.&lt;h4>Methods and results&lt;/h4>The CL of 170 consecutive ACS patients were investigated by optical coherence tomography (OCT) and simultaneous immunophenotyping by flow cytometric analysis as well as by effector molecule concentration measu</pubmed_abstract><journal>European heart journal</journal><pubmed_title>Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study.</pubmed_title><pmcid>PMC7780480</pmcid><funding_grant_id>1R01HL134892</funding_grant_id><funding_grant_id>81Z2100202</funding_grant_id><funding_grant_id>R01 HL134892</funding_grant_id><funding_grant_id>18CSA34080399</funding_grant_id><pubmed_authors>Landmesser U</pubmed_authors><pubmed_authors>Kia S</pubmed_authors><pubmed_authors>Steiner JK</pubmed_authors><pubmed_authors>Mueller DN</pubmed_authors><pubmed_authors>Flores E</pubmed_authors><pubmed_authors>Stahli BE</pubmed_authors><pubmed_authors>Riedel M</pubmed_authors><pubmed_authors>Rai H</pubmed_authors><pubmed_authors>Rauch-Krohnert U</pubmed_authors><pubmed_authors>Abdelwahed YS</pubmed_authors><pubmed_authors>Krankel N</pubmed_authors><pubmed_authors>Leistner DM</pubmed_authors><pubmed_authors>Mochmann HC</pubmed_authors><pubmed_authors>Volk HD</pubmed_authors><pubmed_authors>Sieronski L</pubmed_authors><pubmed_authors>Klotsche J</pubmed_authors><pubmed_authors>Strassler E</pubmed_authors><pubmed_authors>Haghikia A</pubmed_authors><pubmed_authors>Meteva D</pubmed_authors><pubmed_authors>Lauten A</pubmed_authors><pubmed_authors>Frohlich G</pubmed_authors><pubmed_authors>Libby P</pubmed_authors><pubmed_authors>Dirks F</pubmed_authors><pubmed_authors>Joner M</pubmed_authors><pubmed_authors>Skurk C</pubmed_authors><pubmed_authors>Seppelt C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study.</name><description>&lt;h4>Aims&lt;/h4>Acute coronary syndromes with intact fibrous cap (IFC-ACS), i.e. caused by coronary plaque erosion, account for approximately one-third of ACS. However, the underlying pathophysiological mechanisms as compared with ACS caused by plaque rupture (RFC-ACS) remain largely undefined. The prospective translational OPTICO-ACS study programme investigates for the first time the microenvironment of ACS-causing culprit lesions (CL) with intact fibrous cap by molecular high-resolution intracoronary imaging and simultaneous local immunological phenotyping.&lt;h4>Methods and results&lt;/h4>The CL of 170 consecutive ACS patients were investigated by optical coherence tomography (OCT) and simultaneous immunophenotyping by flow cytometric analysis as well as by effector molecule concentration measu</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2026-04-07T16:13:48.962Z</modification><creation>2025-04-06T00:00:57.896Z</creation></dates><accession>S-EPMC7780480</accession><cross_references><pubmed>33080003</pubmed><doi>10.1093/eurheartj/ehaa703</doi></cross_references></HashMap>